Result of General Meeting
Summary by AI BETAClose X
7 September 2026
TheraCryf plc
("TheraCryf", the "Company" or the "Group")
Result of General Meeting
TheraCryf plc, the biotech company developing new medicines for addiction and other neuropsychiatric disorders, announces that at the General Meeting held earlier today, all resolutions were duly passed.
Accordingly, the proposed Capital Raising of approximately £1.05 million (before expenses), comprising the Placing and Subscription announced on 20 August 2026, and the Subdivision of the Company's existing ordinary share capital have been approved by Shareholders.
Under the Subdivision, each Existing Ordinary Share of 0.25 pence will be subdivided into one new Ordinary Share of 0.05 pence ("New Ordinary Shares") and four Deferred Shares of 0.05 pence each. The purpose of the Deferred Shares is solely to facilitate the reduction in the nominal value of the Existing Ordinary Shares to 0.05 pence each. The Deferred Shares created will be effectively valueless as they will not carry any rights to vote or dividend rights, nor will they be admitted to trading on AIM. No share certificates will be issued in respect of the Deferred Shares, nor will CREST accounts of Shareholders be credited in respect of any entitlement to Deferred Shares.
No new share certificates representing the New Ordinary Shares will be sent to Shareholders who hold Existing Ordinary Shares in certificated form following the Subdivision. Accordingly, share certificates for the Existing Ordinary Shares will remain valid, and will only be replaced when the old share certificates are surrendered for cancellation following the transfer, transmission or other disposal of New Ordinary Shares.
The nominal value of shares already held in CREST will be updated at approximately 8.00 a.m. on 9 September 2026. Following completion of the Subdivision, the New Ordinary Shares will have the same rights (save as to nominal value) as the Existing Ordinary Shares, including voting, dividend and other rights. The record date for the Subdivision is 6.00 p.m. on 8 September 2026.
Application has been made for the 583,333,328 New Ordinary Shares being issued pursuant to the Capital Raising to be admitted to trading on AIM. Admission is expected to become effective, and dealings in the Enlarged Share Capital are expected to commence at 8.00 a.m. on 9 September 2026.
Following Subdivision and Admission, the Company will have 2,732,297,067 New Ordinary Shares in issue. The Company holds no shares in treasury. Accordingly, the total number of voting rights in the Company following Subdivision and Admission will be 2,732,297,067.
This figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Unless otherwise defined, capitalised terms used in this announcement have the meanings given to them in the Company's announcement of 20 August 2026 and the Circular published in connection with the General Meeting.
-Ends-
Enquiries
|
TheraCryf plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, COO
|
+44 (0)1625 315 090 enquiries@theracryf.com |
|
Singer Capital Markets (NOMAD & Joint Broker)
|
+44 (0)20 7496 3000 |
|
Turner Pope Investments (Joint Broker) Guy McDougall / Andy Thacker
|
+44 (0)20 3657 0050
|
|
Northstar Communications (Investor Relations) Sarah Hollins |
+44 (0)113 730 3896 sarah@northstarcommunications.co.uk
|
About TheraCryf
TheraCryf plc is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of significant unmet medical need.
The Group's lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders.
The programme has already been heavily de-risked for both safety/tolerability and efficacy in previous testing and is fully funded through final pre-clinical trials to clinical readiness, with regulatory submissions for first in man studies targeted for 2026.
TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01.
The Group operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with commercially focused pharmaceutical and biotechnology companies.
TheraCryf's headquarters and registered office are at Alderley Park, Cheshire.
For further information, visit: https://theracryf.com
Director/PDMR Shareholding
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.
Notification of Dealing Forms:
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
1. Dr Alastair Smith 2. Dr Huw Jones 3. Toni Haenninen* 4. Dr Helen Kuhlman 5. Dr Glen Clack 6. Dr Nicholas Mallard 7. Northern Standard Limited |
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
1. Non-Executive Chair 2. Chief Executive Officer 3. Chief Financial Officer 4. Chief Operating Officer 5. Chief Medical Officer 6. Development Project Leader 7. PCA with Ed Wardle, Non Executive Director
|
||||
|
b) |
Initial notification / Amendment |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a) |
Name |
TheraCryf PLC |
||||
|
b) |
LEI |
213800NO3E6TSTQO8K20 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument
|
Ordinary shares of 0.05p each |
||||
|
b) |
Identification code |
ISIN: GB00BSVYN304 |
||||
|
c) |
Nature of the transaction |
Purchase of Ordinary Shares |
||||
|
d) |
Price(s) and volume(s) |
|
||||
|
e) |
Aggregated information · Price · Aggregated volume |
N/A
|
||||
|
f) |
Date of the transaction |
20 August 2026 |
||||
|
g) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
||||
* Toni Hänninen is participating via Borealito GmbH (a company wholly owned by him).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 9 minutes ago Blackrock Frontiers Investment Trust
- 14 minutes ago Sunda Energy
- 26 minutes ago Avon Technologies plc
- 32 minutes ago Thungela Resources Limited NPV (DI)
- 32 minutes ago Thungela Resources Limited NPV (DI)